{
    "clinical_study": {
        "@rank": "1592", 
        "arm_group": [
            {
                "arm_group_label": "Active", 
                "arm_group_type": "Experimental", 
                "description": "Stendra 200 mg"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to see if Stendra causes any changes in vision, eye pressure,\n      pupil dilation, and color vision in healthy males."
        }, 
        "brief_title": "Safety Study Looking at the Effects of Stendra on Vision", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Vision", 
        "detailed_description": {
            "textblock": "The objectives of this study are to assess the effect of Stendra on visual acuity,\n      intraocular pressure, pupillometry, and color vision discrimination in healthy male\n      subjects."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy adult males 18 to 45 years of age, inclusive\n\n          -  Non-tobacco user for at least 6 months prior to first dose\n\n        Exclusion Criteria:\n\n          -  History or presence of retinal disease or any vision defects including color vision\n\n          -  Intraocular pressure value \u2265 22mm Hg\n\n          -  Resting heart rate < 45 or > 90 beats per minute (3 rechecks)\n\n          -  Systolic blood pressure < 90 or > 140 mm Hg or Diastolic blood pressure < 50 or >90\n             mm Hg (3 rechecks)\n\n          -  Initiation or change in dose of any \u03b1-blockers 14 days prior to randomization"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02033200", 
            "org_study_id": "TA-402"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Active", 
                    "Placebo"
                ], 
                "intervention_name": "Stendra 200 mg", 
                "intervention_type": "Drug", 
                "other_name": "avanafil"
            }, 
            {
                "arm_group_label": [
                    "Active", 
                    "Placebo"
                ], 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "vision", 
            "Stendra", 
            "avanafil", 
            "PDE5 inhibitor", 
            "visual acuity", 
            "intraocular pressure", 
            "pupillometry", 
            "color vision discrimination", 
            "healthy males"
        ], 
        "lastchanged_date": "March 18, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tempe", 
                    "country": "United States", 
                    "state": "Arizona", 
                    "zip": "85283"
                }, 
                "name": "Celerion Inc"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Double-Blind, Randomized, Placebo-Controlled, Single-Dose, Parallel Study to Assess the Effects of Avanafil (STENDRA\u2122) on Multiple Parameters of Vision, Including, But Not Limited to Visual Acuity, Intraocular Pressure, Pupillometry, and Color Vision Discrimination, in Healthy Male Subjects", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Effect of Stendra 1 hour post dosing on color vision discrimination", 
                "safety_issue": "Yes", 
                "time_frame": "1 hour"
            }, 
            {
                "measure": "Effect of Stendra 1 hour post dosing on visual acuity", 
                "safety_issue": "Yes", 
                "time_frame": "1 hour"
            }, 
            {
                "measure": "Effect of Stendra 1 hour post dosing pupil dilation", 
                "safety_issue": "Yes", 
                "time_frame": "1 hour"
            }, 
            {
                "measure": "Effect of Stendra 1 hour post dosing on Intraocular pressure", 
                "safety_issue": "Yes", 
                "time_frame": "1 hour"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02033200"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Effect of Stendra 24 hours post dosing on visual acuity", 
                "safety_issue": "Yes", 
                "time_frame": "24 hours"
            }, 
            {
                "measure": "Effect of Stendra 24 hour post dosing on pupil dilation", 
                "safety_issue": "Yes", 
                "time_frame": "24 hour"
            }, 
            {
                "measure": "Effect of Stendra 24 hour post dosing on color vision discrimination", 
                "safety_issue": "Yes", 
                "time_frame": "24 hours"
            }, 
            {
                "measure": "Effect of Stendra 24 hour post dosing on intraocular pressure", 
                "safety_issue": "Yes", 
                "time_frame": "24 hours"
            }
        ], 
        "source": "VIVUS, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "VIVUS, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}